Posted inCardiagtech

Differential Diagnosis for Proteinuria: A Comprehensive Guide for Clinicians

No Comments

Introduction to Proteinuria

Proteinuria, the presence of excess protein in urine, is a frequently encountered clinical finding in both outpatient and inpatient settings. Its detection often necessitates further investigation, particularly when associated with comorbidities. With the global rise in diabetes prevalence, proteinuria is becoming increasingly common. The primary cause typically involves a disruption in the kidney’s filtration system, though it can also arise from benign conditions. Proteinuria, alongside estimated glomerular filtration rate (eGFR), is now integral to the classification of chronic kidney disease (CKD). It serves as an early warning sign for renal dysfunction and signals an elevated risk of kidney damage linked to hypertension and cardiovascular diseases. The severity of proteinuria often correlates with the progression of underlying diseases. This article aims to provide a detailed guide to the differential diagnosis of proteinuria, enhancing the clinician’s ability to evaluate and manage this condition effectively.

Classifying Proteinuria: Transient vs. Persistent

Proteinuria is broadly categorized into transient and persistent forms, each with distinct clinical implications and differential diagnoses.

Transient Proteinuria: Common Causes

Transient proteinuria is often benign and self-limiting, frequently associated with temporary physiological stressors. Common causes include:

  • Urinary Tract Infections (UTIs): Inflammation and infection within the urinary tract can lead to temporary protein leakage.
  • Orthostatic Proteinuria: This occurs when protein excretion increases in the upright position and is normal in the early morning. It is more common in adolescents and young adults and less frequent after age 30.
  • Fever: Febrile illnesses can temporarily increase glomerular permeability, resulting in proteinuria.
  • Strenuous Exercise: Intense physical activity can cause transient proteinuria due to increased renal blood flow and glomerular pressure.
  • Vaginal Contamination: In females, vaginal mucus can sometimes contaminate urine samples, leading to false-positive proteinuria results.
  • Pregnancy: Hormonal and hemodynamic changes during pregnancy can sometimes cause mild transient proteinuria.

Persistent Proteinuria: Benign and Pathological Etiologies

Persistent proteinuria, as the name suggests, is detected on repeated urinalysis and is more likely to indicate underlying kidney damage or systemic disease. It can be further subdivided into benign and pathological causes.

Benign Causes of Persistent Proteinuria:

  • Fever and Acute Illness: While often transient, proteinuria associated with fever or acute illness can sometimes persist until full recovery.
  • Exercise/Intense Physical Activity: In some individuals, particularly athletes, exercise-induced proteinuria may be more persistent.
  • Orthostatic Proteinuria: Though typically transient, orthostatic proteinuria can be persistent in some individuals.
  • Dehydration: Reduced renal blood flow due to dehydration can concentrate urine and lead to detectable proteinuria.
  • Emotional Stress: Significant emotional stress can sometimes contribute to persistent proteinuria.
  • Heat Injury: Exposure to extreme heat can cause renal stress and proteinuria.
  • Inflammatory Processes: Systemic inflammation, even from non-renal conditions, can sometimes cause persistent proteinuria.

Pathological Causes of Persistent Proteinuria:

Pathological persistent proteinuria signifies underlying renal or systemic disease. These causes are further categorized based on the mechanism of proteinuria.

Understanding the Pathophysiology to Guide Differential Diagnosis

To effectively approach the differential diagnosis of proteinuria, understanding the underlying pathophysiology is crucial. Proteinuria arises from disruptions in one or more of the following renal mechanisms:

Glomerular Proteinuria: Mechanisms and Causes

Glomerular proteinuria, the most common type, results from damage to the glomerular filtration barrier. This barrier, composed of the glomerular endothelium, basement membrane, and podocytes, normally restricts the passage of large proteins like albumin. Dysfunction can arise from:

  • Glomerular Basement Membrane Damage: Diseases like diabetic nephropathy, glomerulonephritis, and lupus nephritis damage the glomerular basement membrane, increasing permeability to proteins.
  • Podocyte Injury: Podocytes, specialized epithelial cells, are critical for filtration. Conditions like focal segmental glomerulosclerosis (FSGS) and minimal change disease directly injure podocytes, leading to significant proteinuria.
  • Charge Barrier Disruption: The glomerular capillary wall has a negative charge, repelling negatively charged proteins like albumin. Loss of this charge barrier, often due to glomerular disease, contributes to proteinuria.
  • Increased Glomerular Hydrostatic Pressure: Conditions like hypertension can increase pressure within the glomeruli, forcing more protein across the filtration barrier.

Common Causes of Glomerular Proteinuria:

  • Diabetic Nephropathy (most prevalent cause of chronic kidney disease and glomerular proteinuria)
  • Primary Glomerulonephropathies (e.g., IgA nephropathy, membranous nephropathy, FSGS, minimal change disease)
  • Secondary Glomerulonephropathies (e.g., lupus nephritis, Henoch-Schönlein purpura, amyloidosis)
  • Drug-Induced Nephropathy (NSAIDs, lithium, gold, penicillamine)
  • Infections (HIV-associated nephropathy, hepatitis B and C, post-streptococcal glomerulonephritis)
  • Malignancies (paraneoplastic glomerulopathy, lymphoma, multiple myeloma)
  • Connective Tissue Diseases (systemic lupus erythematosus, rheumatoid arthritis)
  • Preeclampsia

Tubular Proteinuria: Mechanisms and Causes

Tubular proteinuria occurs when the proximal tubules are unable to reabsorb normally filtered low-molecular-weight proteins. In healthy individuals, most filtered proteins are reabsorbed in the proximal tubules. Tubular dysfunction can result from:

  • Proximal Tubular Damage: Conditions like acute tubular necrosis (ATN), tubulointerstitial nephritis, and nephrotoxic drug exposure damage proximal tubular cells, impairing reabsorption.
  • Reduced Tubular Reabsorptive Capacity: In certain conditions, the reabsorptive capacity of the tubules may be overwhelmed, leading to proteinuria.

Common Causes of Tubular Proteinuria:

  • Tubulointerstitial Nephritis (acute and chronic)
  • Hypertensive Nephrosclerosis
  • Polycystic Kidney Disease
  • Nephrotoxic Agents (aminoglycosides, cisplatin, contrast media)
  • Heavy Metal Poisoning (lead, cadmium)

Overflow and Secretory Proteinuria: Mechanisms and Causes

Overflow Proteinuria: This type occurs when there is an overproduction of certain low-molecular-weight proteins that overwhelm the tubules’ reabsorptive capacity.

Common Causes of Overflow Proteinuria:

  • Multiple Myeloma (Bence-Jones proteinuria – light chain proteins)
  • Myoglobinuria (rhabdomyolysis)
  • Hemoglobinuria (hemolytic anemia)
  • Amyloidosis (light chain amyloidosis)

Secretory Proteinuria: This is caused by the kidneys themselves secreting proteins into the urine.

Common Causes of Secretory Proteinuria:

  • Tamm-Horsfall Protein (uromodulin) overproduction (can be increased in some kidney diseases but is generally not clinically significant in differential diagnosis of pathological proteinuria).

Clinical Evaluation and Diagnostic Approach to Proteinuria

A systematic approach is essential to effectively evaluate and establish a Differential Diagnosis For Proteinuria.

History and Physical Examination Clues

A detailed history and physical exam can provide valuable clues to the etiology of proteinuria. Key historical points include:

  • Symptoms of Renal Disease: Edema (leg swelling), fatigue, changes in urine output, foamy urine (suggestive of nephrotic syndrome).
  • Symptoms of Systemic Disease: Joint pain (arthralgias), skin rashes, mouth ulcers (suggestive of connective tissue diseases like lupus).
  • History of Hypertension, Diabetes, Heart Failure: These are major risk factors for CKD and diabetic nephropathy.
  • Medication History: Review for nephrotoxic drugs (NSAIDs, ACE inhibitors, ARBs, lithium, aminoglycosides).
  • Family History: Family history of kidney disease, glomerulonephritis, or systemic diseases.
  • Recent Infections: Post-streptococcal glomerulonephritis typically follows a streptococcal infection.
  • Changes in Urine Appearance: Red or smoky urine (hematuria), frothy urine (proteinuria).

The physical examination should focus on:

  • Blood Pressure Measurement: Hypertension is commonly associated with renal disease and proteinuria.
  • Edema Assessment: Presence and severity of edema (peripheral, periorbital, ascites).
  • Signs of Systemic Disease: Skin rashes (lupus, vasculitis), joint swelling (arthritis), signs of heart failure (JVD, lung crackles), abdominal bruits (renal artery stenosis).

Initial Laboratory Evaluation: Urine Dipstick and Quantification

The initial screening for proteinuria often involves a urine dipstick test.

  • Urine Dipstick: This is a semi-quantitative test that detects primarily albumin. It provides a quick assessment but can have false positives (concentrated urine, alkaline urine, UTI, hematuria) and false negatives (dilute urine, non-albumin proteins). A positive dipstick warrants further quantitative testing.

Further Investigations: UPCR, UACR, and Renal Function Tests

For quantitative assessment of proteinuria, the following tests are crucial:

  • Urine Protein-to-Creatinine Ratio (UPCR): This spot urine test is a reliable estimate of 24-hour protein excretion and is preferred over 24-hour urine collection due to convenience and accuracy. A UPCR > 15 mg/mmol is considered abnormal.
  • Urine Albumin-to-Creatinine Ratio (UACR): This is more sensitive for detecting early proteinuria, particularly albuminuria, and is recommended in patients at risk for CKD. A UACR > 3 mg/mmol is abnormal.
  • Serum Creatinine and eGFR: Assess renal function. Elevated creatinine and reduced eGFR indicate kidney impairment.
  • Serum Albumin: Low serum albumin levels, especially in conjunction with nephrotic range proteinuria (UPCR > 350 mg/mmol), suggest nephrotic syndrome.
  • Lipid Panel: Hyperlipidemia is common in nephrotic syndrome.

Imaging and Serological Tests

Depending on the suspected etiology based on history, physical exam, and initial labs, further investigations may include:

  • Renal Ultrasound: To assess kidney size, echogenicity, and rule out hydronephrosis or structural abnormalities.
  • Immunological Tests:
    • ANA, Anti-dsDNA, Complement Levels (C3, C4): For suspected lupus nephritis.
    • ANCA: For suspected vasculitis (e.g., granulomatosis with polyangiitis, microscopic polyangiitis).
    • Anti-GBM Antibodies: For suspected anti-glomerular basement membrane disease (Goodpasture’s syndrome).
    • Serum and Urine Protein Electrophoresis: To detect monoclonal proteins (Bence-Jones proteins) in multiple myeloma or other plasma cell dyscrasias.
    • Hepatitis B and C Serologies, HIV testing: To evaluate for infection-related glomerulonephritis.

When to Consider Renal Biopsy

Renal biopsy is often indicated in patients with persistent proteinuria, especially when:

  • Nephrotic range proteinuria (UPCR > 350 mg/mmol).
  • Unexplained proteinuria with declining renal function.
  • Proteinuria associated with hematuria or systemic features.
  • To guide therapy and prognosis in glomerular diseases.

Differential Diagnosis of Proteinuria: A Detailed Breakdown

Based on the pathophysiological mechanisms and clinical evaluation, the differential diagnosis of proteinuria can be systematically approached.

Glomerular Disorders

  • Primary Glomerulonephropathies:

    • Minimal Change Disease
    • Focal Segmental Glomerulosclerosis (FSGS)
    • Membranous Nephropathy
    • IgA Nephropathy (Berger’s Disease)
    • Membranoproliferative Glomerulonephritis

  • Secondary Glomerulonephropathies:

    • Diabetic Nephropathy
    • Lupus Nephritis
    • Amyloidosis
    • Post-infectious Glomerulonephritis (Post-streptococcal, HIV-associated, Hepatitis B/C associated)
    • Henoch-Schönlein Purpura
    • Goodpasture’s Syndrome
    • Vasculitis-associated glomerulonephritis (ANCA-associated, cryoglobulinemic vasculitis)

Tubulointerstitial Diseases

  • Acute Tubulointerstitial Nephritis (AIN) – drug-induced, infection-related, idiopathic
  • Chronic Tubulointerstitial Nephritis – reflux nephropathy, analgesic nephropathy, heavy metal nephropathy, hypertensive nephrosclerosis
  • Polycystic Kidney Disease
  • Medullary Cystic Kidney Disease

Systemic Diseases with Renal Manifestations

  • Systemic Lupus Erythematosus (SLE)
  • Rheumatoid Arthritis
  • Sjogren’s Syndrome
  • Multiple Myeloma and other Plasma Cell Dyscrasias
  • Amyloidosis
  • Sarcoidosis

Benign and Transient Conditions

  • Transient Proteinuria (fever, exercise, orthostatic, UTI, pregnancy)
  • Benign Persistent Proteinuria (isolated persistent proteinuria without progressive renal disease, often mild)

Overflow Proteinuria Conditions

  • Multiple Myeloma (Light Chain Proteinuria/Bence-Jones Proteinuria)
  • Rhabdomyolysis (Myoglobinuria)
  • Hemolytic Anemia (Hemoglobinuria)

Management Strategies Based on Differential Diagnosis

Management of proteinuria is directed at treating the underlying cause and reducing proteinuria itself to slow kidney disease progression and minimize complications.

Treatment of Underlying Conditions

  • Diabetic Nephropathy: Strict glycemic control, blood pressure management (ACE inhibitors or ARBs), SGLT2 inhibitors.
  • Glomerulonephritis: Immunosuppression (corticosteroids, cyclophosphamide, mycophenolate mofetil), ACE inhibitors/ARBs. Specific treatment depends on the type of glomerulonephritis identified by biopsy.
  • Lupus Nephritis: Immunosuppression, blood pressure control.
  • Multiple Myeloma: Chemotherapy, stem cell transplant.
  • Urinary Tract Infections: Antibiotics.
  • Drug-induced Nephropathy: Discontinuation of offending drug.

Renoprotective Strategies: RAAS Blockade and Beyond

Regardless of the underlying cause, reducing proteinuria itself is a key therapeutic goal.

  • ACE Inhibitors and Angiotensin Receptor Blockers (ARBs): First-line agents to reduce proteinuria, particularly albuminuria, by reducing glomerular pressure and improving filtration selectivity. Recommended for persistent proteinuria > 300 mg/24 hours.
  • Aldosterone Antagonists (Spironolactone, Eplerenone): Can be added to ACE inhibitors or ARBs for further proteinuria reduction, especially in resistant cases and in heart failure. Monitor potassium levels closely.
  • Calcium Channel Blockers (Non-dihydropyridine): Diltiazem and verapamil can reduce proteinuria, though less effectively than ACE inhibitors/ARBs.
  • SGLT2 Inhibitors: Emerging evidence suggests renoprotective benefits and proteinuria reduction in diabetic and non-diabetic kidney disease.
  • Dietary Salt Restriction: Reduces fluid retention and can help manage proteinuria.
  • Diuretics: To manage edema associated with nephrotic syndrome.

Prognosis and Complications: Implications of Proteinuria

Proteinuria is not merely a laboratory finding; it is a significant prognostic marker and is associated with numerous complications.

  • Prognostic Indicator: Higher levels of proteinuria are associated with faster progression of CKD, increased risk of cardiovascular events, and mortality. Remission of proteinuria improves prognosis in many glomerular diseases.
  • Increased Cardiovascular Risk: Proteinuria is an independent risk factor for coronary heart disease, cerebrovascular disease, and peripheral artery disease.
  • Progression to End-Stage Renal Disease (ESRD): Persistent proteinuria accelerates kidney function decline and increases the likelihood of requiring dialysis or kidney transplantation.
  • Hypercoagulability and Thrombosis: Nephrotic range proteinuria increases the risk of venous thromboembolism, including deep vein thrombosis and pulmonary embolism.
  • Other Complications: Fluid overload, pulmonary edema, increased susceptibility to infections, gastrointestinal hemorrhage.

Interprofessional Approach to Proteinuria Management

Effective management of proteinuria requires a collaborative interprofessional team:

  • Primary Care Physician: Initial detection, evaluation, and referral.
  • Nephrologist: Specialist in kidney disease, essential for diagnosis, management of complex cases, and renal biopsy interpretation.
  • Immunologist/Rheumatologist: For management of systemic autoimmune diseases causing proteinuria.
  • Endocrinologist: For management of diabetic nephropathy.
  • Cardiologist: For management of cardiovascular complications.
  • Pharmacist: Medication management and reconciliation, especially regarding RAAS inhibitors and diuretics.
  • Dietitian: Dietary counseling, especially salt restriction.
  • Nursing Staff: Patient education, monitoring, and care coordination.

Conclusion: Navigating the Differential Diagnosis of Proteinuria

Proteinuria is a common and significant clinical finding that requires a systematic and thorough approach to differential diagnosis. Understanding the various classifications, pathophysiological mechanisms, and diagnostic modalities is crucial for clinicians. By considering the broad range of potential causes, from transient benign conditions to severe glomerular and systemic diseases, and employing a comprehensive evaluation strategy, clinicians can effectively manage proteinuria, mitigate its complications, and improve patient outcomes. Early recognition, accurate diagnosis, and targeted treatment are paramount in slowing the progression of kidney disease and reducing the associated cardiovascular risks linked to proteinuria.

References

  1. Grauer GF. Proteinuria: measurement and interpretation. Top Companion Anim Med. 2011 Aug;26(3):121-7.
  2. Hoyer JR, Seiler MW. Pathophysiology of Tamm-Horsfall protein. Kidney Int. 1979 Sep;16(3):279-89.
  3. Lamb EJ, MacKenzie F, Stevens PE. How should proteinuria be detected and measured? Ann Clin Biochem. 2009 May;46(Pt 3):205-17.
  4. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G., National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003 Jul 15;139(2):137-47.
  5. Verma V, Kant R, Sunnoqrot N, Gambert SR. Proteinuria in the elderly: evaluation and management. Int Urol Nephrol. 2012 Dec;44(6):1745-51.
  6. Clase CM, Gao P, Tobe SW, McQueen MJ, Grosshennig A, Teo KK, Yusuf S, Mann JF., ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and TRANSCEND (Telmisartan Randomized Assessment Study in Angiotensin-Converting-Enzyme-Inhibitor Intolerant Subjects with Cardiovascular Disease). Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study. Ann Intern Med. 2011 Mar 01;154(5):310-8.
  7. Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS, Jong PE, Coresh J, Chronic Kidney Disease Prognosis Consortium. Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS, de Jong PE, Coresh J, El-Nahas M, Eckardt KU, Kasiske BL, Wright J, Appel L, Greene T, Levin A, Djurdjev O, Wheeler DC, Landray MJ, Townend JN, Emberson J, Clark LE, Macleod A, Marks A, Ali T, Fluck N, Prescott G, Smith DH, Weinstein JR, Johnson ES, Thorp ML, Wetzels JF, Blankestijn PJ, van Zuilen AD, Menon V, Sarnak M, Beck G, Kronenberg F, Kollerits B, Froissart M, Stengel B, Metzger M, Remuzzi G, Ruggenenti P, Perna A, Heerspink HJ, Brenner B, de Zeeuw D, Rossing P, Parving HH, Auguste P, Veldhuis K, Wang Y, Camarata L, Thomas B, Manley T. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011 Jun;79(12):1331-40.
  8. Snyder S, John JS. Workup for proteinuria. Prim Care. 2014 Dec;41(4):719-35.
  9. Haynes J, Haynes R. Proteinuria. BMJ. 2006 Feb 04;332(7536):284.
  10. Nielsen R, Christensen EI. Proteinuria and events beyond the slit. Pediatr Nephrol. 2010 May;25(5):813-22.
  11. National Collaborating Centre for Chronic Conditions (UK). Chronic Kidney Disease: National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care. Royal College of Physicians (UK); London: Sep, 2008.
  12. Uehara K, Tominaga N, Shibagaki Y. Adult orthostatic proteinuria. Clin Kidney J. 2014 Jun;7(3):327-8.
  13. Bökenkamp A. Proteinuria-take a closer look! Pediatr Nephrol. 2020 Apr;35(4):533-541.
  14. Gurung R, Li T. Renal Amyloidosis: Presentation, Diagnosis, and Management. Am J Med. 2022 Apr;135 Suppl 1:S38-S43.
  15. Kohler M, Schänzer W, Thevis M. Effects of exercise on the urinary proteome. Adv Exp Med Biol. 2015;845:121-31.
  16. Lim D, Lee DY, Cho SH, Kim OZ, Cho SW, An SK, Kim HW, Moon KH, Lee MH, Kim B. Diagnostic accuracy of urine dipstick for proteinuria in older outpatients. Kidney Res Clin Pract. 2014 Dec;33(4):199-203.
  17. Tomonaga Y, Risch L, Szucs TD, Ambühl PM. The prevalence of chronic kidney disease in a primary care setting: a Swiss cross-sectional study. PLoS One. 2013;8(7):e67848.
  18. White SL, Yu R, Craig JC, Polkinghorne KR, Atkins RC, Chadban SJ. Diagnostic accuracy of urine dipsticks for detection of albuminuria in the general community. Am J Kidney Dis. 2011 Jul;58(1):19-28.
  19. Bezinque A, Noyes SL, Kirmiz S, Parker J, Dey S, Kahnoski RJ, Lane BR. Prevalence of Proteinuria and Other Abnormalities in Urinalysis Performed in the Urology Clinic. Urology. 2017 May;103:34-38.
  20. Yamagata K, Iseki K, Nitta K, Imai H, Iino Y, Matsuo S, Makino H, Hishida A. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol. 2008 Feb;12(1):1-8.
  21. Jones CA, Francis ME, Eberhardt MS, Chavers B, Coresh J, Engelgau M, Kusek JW, Byrd-Holt D, Narayan KM, Herman WH, Jones CP, Salive M, Agodoa LY. Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2002 Mar;39(3):445-59.
  22. Bryson CL, Ross HJ, Boyko EJ, Young BA. Racial and ethnic variations in albuminuria in the US Third National Health and Nutrition Examination Survey (NHANES III) population: associations with diabetes and level of CKD. Am J Kidney Dis. 2006 Nov;48(5):720-6.
  23. Liu D, Lv LL. New Understanding on the Role of Proteinuria in Progression of Chronic Kidney Disease. Adv Exp Med Biol. 2019;1165:487-500.
  24. Gong R, Wang P, Dworkin L. What we need to know about the effect of lithium on the kidney. Am J Physiol Renal Physiol. 2016 Dec 01;311(6):F1168-F1171.
  25. Sfrijan D, Tieranu I, Necula I, Popa L, Balgradean M. Nephrotic Syndrome, Paraneoplastic Syndrome Associated to Hodgkin Lymphoma. Maedica (Bucur). 2016 Mar;11(1):64-67.
  26. Leung AK, Wong AH, Barg SS. Proteinuria in Children: Evaluation and Differential Diagnosis. Am Fam Physician. 2017 Feb 15;95(4):248-254.
  27. Uva L, Miguel D, Pinheiro C, Freitas JP, Marques Gomes M, Filipe P. Cutaneous manifestations of systemic lupus erythematosus. Autoimmune Dis. 2012;2012:834291.
  28. Ağbaş A, Bay ED, Başaran MK, İkizceli T, Kayhan GK, Özlük Y. Nephrotic range proteinuria in an adolescent with a diagnosis of Wilson’s disease: Answers. Pediatr Nephrol. 2021 Jul;36(7):2103-2106.
  29. WILLS MR, MCGOWAN GK. THE RELIABILITY OF THE ALBUSTIX TEST FOR PROTEINURIA. J Clin Pathol. 1963 Sep;16(5):487.
  30. Pugia MJ, Lott JA, Profitt JA, Cast TK. High-sensitivity dye binding assay for albumin in urine. J Clin Lab Anal. 1999;13(4):180-7.
  31. Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int. 2016 Jul;90(1):41-52.
  32. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985 Apr;33(4):278-85.
  33. Ozkok A, Yildiz A. Hepatitis C virus associated glomerulopathies. World J Gastroenterol. 2014 Jun 28;20(24):7544-54.
  34. Lyubimova NV, Timofeev YS, Abaev VM, Votyakova OM, Kushlinskii NE. Immunochemical Diagnosis of Multiple Myeloma. Bull Exp Biol Med. 2018 May;165(1):84-87.
  35. Athavale A, Roberts DM. Management of proteinuria: blockade of the renin-angiotensin-aldosterone system. Aust Prescr. 2020 Aug;43(4):121-125.
  36. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993 Nov 11;329(20):1456-62.
  37. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997 Jun 28;349(9069):1857-63.
  38. Bakris GL. Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol. 2008 Jan;3 Suppl 1(Suppl 1):S3-10.
  39. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266.
  40. ONTARGET Investigators. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 Apr 10;358(15):1547-59.
  41. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 02;341(10):709-17.
  42. Carmines PK, Navar LG. Disparate effects of Ca channel blockade on afferent and efferent arteriolar responses to ANG II. Am J Physiol. 1989 Jun;256(6 Pt 2):F1015-20.
  43. Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int. 1998 Sep;54(3):889-96.
  44. Tanacan A, Fadiloglu E, Beksac MS. The importance of proteinuria in preeclampsia and its predictive role in maternal and neonatal outcomes. Hypertens Pregnancy. 2019 May;38(2):111-118.
  45. Tsampalieros A, Knoll GA. Evaluation and Management of Proteinuria After Kidney Transplantation. Transplantation. 2015 Oct;99(10):2049-60.
  46. Reich HN, Troyanov S, Scholey JW, Cattran DC., Toronto Glomerulonephritis Registry. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007 Dec;18(12):3177-83.
  47. Iimori S, Naito S, Noda Y, Sato H, Nomura N, Sohara E, Okado T, Sasaki S, Uchida S, Rai T. Prognosis of chronic kidney disease with normal-range proteinuria: The CKD-ROUTE study. PLoS One. 2018;13(1):e0190493.
  48. Chen X, Chen Y, Ding X, Zhou Y, Lv Y, Li D, Chen B, Chen T, Chen C. Baseline proteinuria level is associated with prognosis in idiopathic membranous nephropathy. Ren Fail. 2019 Nov;41(1):363-369.
  49. Naderi AS, Reilly RF. Primary care approach to proteinuria. J Am Board Fam Med. 2008 Nov-Dec;21(6):569-74.
  50. Perkovic V, Verdon C, Ninomiya T, Barzi F, Cass A, Patel A, Jardine M, Gallagher M, Turnbull F, Chalmers J, Craig J, Huxley R. The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Med. 2008 Oct 21;5(10):e207.
  51. Ishigami J, Grams ME, Naik RP, Coresh J, Matsushita K. Chronic Kidney Disease and Risk for Gastrointestinal Bleeding in the Community: The Atherosclerosis Risk in Communities (ARIC) Study. Clin J Am Soc Nephrol. 2016 Oct 07;11(10):1735-1743.
  52. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol. 2006 Nov;17(11):2974-84.
  53. Gigante A, Barbano B, Sardo L, Martina P, Gasperini ML, Labbadia R, Liberatori M, Amoroso A, Cianci R. Hypercoagulability and nephrotic syndrome. Curr Vasc Pharmacol. 2014 May;12(3):512-7.
  54. Jun M, Ohkuma T, Zoungas S, Colagiuri S, Mancia G, Marre M, Matthews D, Poulter N, Williams B, Rodgers A, Perkovic V, Chalmers J, Woodward M., ADVANCE Collaborative Group. Changes in Albuminuria and the Risk of Major Clinical Outcomes in Diabetes: Results From ADVANCE-ON. Diabetes Care. 2018 Jan;41(1):163-170.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *